GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors

By sjmartinez • September 1, 2024

Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart Fail. 2024 Aug 16:S2213-1779(24)00561-4. doi: 10.1016/j.jchf.2024.07.006. Epub ahead of print. PMID: 39207323.

Tags: Cardiology/Epi, GLP-1 receptor agonists, Heart failure with preserved ejection fraction, Obesity, overweight, Publications, SGLT2is

Macroscopic and microscopic observations of a helix-fixation type leadless pacemaker 1 month after implantation

Miyazaki Y, Rimmer M, Bender AB, Hanna P, Hayase JH, Do DH, Xu S, Ajijola OA, Fishbein MC, Shivkumar K, Mori S. Macroscopic and microscopic[...]

Cardiotoxicity of T cell immunotherapies

Raddatz MA, Stein-Merlob AF, Mahmood SS, Ganatra S, Addison D, Lin TL, Larson SM, Yang EH. Cardiotoxicity of T cell immunotherapies. Nat Rev Cardiol. 2026[...]

Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings

Raman VK, Vargas JD, Moore HJ, Wu WC, Patel SS, Zhang S, Morgan CJ, Lam PH, Heidenreich PA, Lu F, Ahmed AA, Fonarow GC, Ahmed[...]